NEW YORK (GenomeWeb) – Biodesix announced today that it has partnered with the University of Colorado Cancer Center to develop a blood-based assay designed to help identify non-small cell lung cancer (NSCLC) patients likely to respond to certain immunotherapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.